Aktive Positionen von Johan Van Hoof
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
P.J.A. Beheer
 P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | Direktor/Vorstandsmitglied | 01.10.2017 | - |
| Vorstandsvorsitzender | 01.10.2017 | - | |
Ziphius Vaccines NV
 Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Johan Van Hoof
Statistik
International
| Belgien | 3 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
P.J.A. Beheer
P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | Finance |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Health Technology |
- Börse
- Insiders
- Johan Van Hoof
- Erfahrung
